Hybrid cooperative complexes to decrease VAS score and enhance sexual function in women with vulvar lichen sclerosus

• Published in: European review for medical and pharmacological sciences Vol. 28; no. 2; p. 814
• Main Authors: Tedesco, M, Alei, L, Bonadies, A, Pallara, T, Parisi, P, Latini, A, Bellei, B, Sperati, F, Migliano, E
• Format: Journal Article
• Language: English
• Published: Italy 01.01.2024
• ISSN: 2284-0729
• DOI: 10.26355/eurrev_202401_35082

Lichen sclerosus is a chronic, inflammatory, progressive skin disease predominantly affecting anogenital areas. Vulvar lichen sclerosus (VLS) is one of the most common conditions treated in vulvar clinics; most patients report distressing symptoms of itching, burning, stinging, and pain (particularly during or after sexual intercourse). A preliminary, prospective, single-center study was performed to investigate the efficacy of hyaluronan hybrid cooperative complex (HCC) comprising high and low molecular weight hyaluronic acid to treat menopausal women with VLS. Patients (N = 30) received two HCC injections at 32 mg/ml (one month apart). At baseline and one and six months after treatment, patients completed validated psychometric questionnaires to assess their self-reported pain, itching, and dryness using the Visual Analogue Scale (VAS) and sexual function by the Female Sexual Function Index (FSFI). After treatment with HCC, no side effects or complications were reported. VAS scores showed a trend towards reduced pain and itching intensity, and there was a statistically significant reduction in median VAS score for dryness at follow-up vs. baseline (p=0.038). For sexual function, there was a statistically significant improvement in lubrication (p=0.001) and orgasm (p=0.001) FSFI domains. Overall, this preliminary study demonstrated the promising efficacy of HCC in menopausal women with VLS without side effects.